(3.236.231.61) 您好!臺灣時間:2021/05/15 21:29
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

: 
twitterline
研究生:黃敬翔
研究生(外文):Huang,Ching-Hsiang
論文名稱:開發含蝦紅素之固態脂質奈米粒子與奈米結構脂質載體
論文名稱(外文):Development of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) encapsulated Astaxanthin
指導教授:林維炤林維炤引用關係
指導教授(外文):LIN,WEI CHAO
口試委員:林恆弘陳崇裕
口試委員(外文):LIN,HENG HUNGCHEN,CHUNG YU
口試日期:2017-07-04
學位類別:碩士
校院名稱:嘉南藥理大學
系所名稱:化粧品應用與管理系
學門:民生學門
學類:美容學類
論文種類:學術論文
論文出版年:2017
畢業學年度:105
語文別:中文
論文頁數:106
中文關鍵詞:奈米結構脂質載體固態脂質奈米粒子蝦紅素高壓均質法烷基葡萄醣苷經皮吸收
外文關鍵詞:Nanostructured lipid carriersSolid lipid nanoparticlesAstaxnathinHigh pressure homogenizerAlkyl PolyglucosidePercutaneous absorption
相關次數:
  • 被引用被引用:0
  • 點閱點閱:265
  • 評分評分:
  • 下載下載:12
  • 收藏至我的研究室書目清單書目收藏:0
本研究主要藉由脂質載體(lipid-carriers)之結構包覆蝦紅素(Astaxanthin),開發固態脂質奈米粒子(SLNs)與奈米結構脂質載體(NLCs),其目的為避免活性成分氧化且經長時間儲存而降解。本實驗以熱高壓均質乳化(500bar/5 cycles)製備Astaxnthin-SLN與Astaxnthin -NLC,所製備的SLNs與NLCs平均在120 nm-170 nm左右,且有均勻的分散係數(PdI)與穩定的界面電位(Zeta potentail)介於│25│~│41│ mV,全部配方總量回收率皆93 %以上、包埋率100 %。經90天安定性評估,NLCs比SLNs更穩定且不易降解,以烷基葡萄糖苷界面活性劑(Plantacare®2000)製備載體Astaxnthin-NLC(PL2000)有最穩定的配方總量回收率皆88%以上,經皮膚刺激性測試72小時觀察結果為無刺激性。經皮膚保溼度測試實驗人數10人,精華液含NLC(S-NLC)塗抹於臉部,有70%的人保濕度改善(P<0.05)。使用靜態式經皮吸收擴散槽體外研究顯示,以乳液含NLC(E-NLC)有最好的皮膚滲透力與一般製程乳液(T-emulsion)相比有顯著差異(P<0.05),且載體加入乳液中,可改善皮膚滲透力。
The aim of this study was to develop and assess nanostructured lipid carriers(NLCs) compared to solid lipid nanoparticles(SLNs) encapsulated with Astaxanthin. The purpose of the present research was to avoid oxidation and degradation of the active ingredient then prolonged storage time. In this study, Encapsulation of Astaxanthin in SLN (Astaxnthin-SLN) and NLC (Astaxnthin-NLC) were prepared by hot high pressure homogenizer technique (500 bars/5cycles). The results shown that SLNs and NLCs particles were around 120 nm-170 nm diameters with narrow distribution and stable zeta potential(│25│ ~ │41│mV). The total recovery of formulations were more than 93 %, the encapsulation efficiency was 100 % for all tested formulations. The NLC prepared by Cetyl palmitate、Caprylic/Capric triglyceride and surfactant (Plantacare® 2000) was better stability and less degradation than SLN. The total recovery of Astaxanthin-NLC (PL2000) was more than 88 % after storage for 3 months, the skin irritation test results shown Astaxanthin-NLC (PL2000) was non-irritation in 72 hours. The skin efficiency test with 10 volunteers by applying the serum contains NLC (S-NLC) on their face were performed, the results shown that 70 % of people improved in moisture (P<0.05). The in vitro percutaneous absorption with Franz cell results shown that emulsion contains NLC (E-NLC) transdermal permeation of Astaxanthin was greater than Typical-emulsion (T-emulsion), they were significant increased (P < 0.05). These findings indicated that NLC could add to typical-emulsion to improve the skin penetration.
摘要 I
Abstract II
致謝 III
目錄 V
圖目錄 VIII
表目錄 X
第一章、緒論 1
1-1研究動機及目的 2
1-2研究架構 3
第二章、文獻探討 5
2-1奈米載體與皮膚的相互作用 5
2-1-1表皮層(Epidermis) 6
2-1-2真皮層(Dermis) 8
2-1-3皮下組織 ( Subcutaneous Layer ) 8
2-1-4皮膚障壁 (Skin barrier ) 9
2-1-5經皮吸收途徑(Percutaneous absorption) 10
2-2 載體(Carreirs) 12
2-2-1載體介紹 12
2-2-2固態脂質奈米粒子(Solid lipid nanoparticles;SLNs)的組成 13
2-2-3脂質載體(lipid-carrier)的組成 15
2-2-4固態脂質奈米粒子/奈米結構脂質載體之製備方法 27
2-2-5固態脂質奈米粒子(SLNs)與奈米結構脂質載體(NLCs)之結構特性 31
2-2-6 SLNs和NLCs在化粧品應用上的優點 34
2-3 蝦紅素(Astaxanthin) 36
第三章、實驗材料與方法 38
3-1 實驗材料 38
3-2 實驗儀器 40
3-3 實驗方法 42
3-3-1實驗配方 42
3-3-2 SLNs/NLCs製備 42
3-3-3乳液與精華液配方製備 44
3-3-4粒徑與界面電位測量 46
3-3-5分光光譜法與HPLC 分析條件 49
3-3-6總量回收率與包埋率測量 54
3-3-7一般乳液與精華液含蝦紅素之總量回收率 57
3-3-8安定性之分析 57
3-3-9奈米結構脂質載體型態 58
3-3-10皮膚刺激性測試 59
3-3-11奈米結構脂質載體之皮膚有效性評估 60
3-3-12體外經皮吸收試驗( in vitro percutaneous absorption) 61
3-3-13皮膚組織切片 65
3-3-14 資料處理與分析 65
第四章、結果與討論 66
4-1載體配方組成與製備 66
4-2脂質載體包覆蝦紅素之粒徑及界面電位分析 67
4-2載體之總量回收率與包覆率 69
4-2-1載體包覆蝦紅素之總量回收率 69
4-2-2載體包覆蝦紅素之包覆率 69
4-3 載體之安定性 71
4-3-1不同儲存溫度及時間之粒徑大小及界面電位變化 71
4-3-2載體配方包覆蝦紅素於不同儲存溫度及時間之相對於初天總量回收率 78
4-4奈米結構脂質載體型態 84
4-5皮膚刺激性測試 85
4-6奈米結構脂質載體之皮膚保溼性評估 87
4-7體外經皮吸收試驗( in vitro percutaneous absorption) 88
第五章、結論 93
參考文獻 95
附件 104


1.Pardeike, J.; Hommoss, A.; Muller, R. H., Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009, 366, 170-84.
2.Muller, R. H.; Mader, K.; Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 2000, 50, 161-177.
3.Wissing, S.A., Mäder, K., Müller, R. H.: Solid lipid nanoparticles (SLN) as a novel carrier system offereing prolonged release of perfume Allure (Chanel). In: Int. Symp.Control. Release Bioact. Mater., vol. 27, pp. 311–312 (2000)
4.Yiki V., Biological functions and activities of animal carotenoids, Pure&App/. Chem., 1991, 63, 141-146,.
5.Li, M. M.; Zahi, M. R.; Yuan, Q. P.; Tian, F. B.; Liang, H., Preparation and stability of astaxanthin solid lipid nanoparticles based on stearic acid. European Journal of Lipid Science and Technology 2016, 118 , 592-602.
6.Grynbaum, M. D.; Hentschel, P.; Putzbach, K.; Rehbein, J.; Krucker, M.; Nicholson, G.; Albert, K., Unambiguous detection of astaxanthin and astaxanthin fatty acid esters in krill (Euphausia superba Dana). Journal of Separation Science 2005, 28, 1685-1693.
7.Toasa, S.; Cakli, S.; Ostermeyer, U., Determination of astaxanthin and canthaxanthin in salmonid. European Food Research and Technology 2005, 221, 787-791.
8.Stiefel, C.; Schwack, W., Photoprotection in changing times - UV filter efficacy and safety, sensitization processes and regulatory aspects. International Journal of Cosmetic Science 2015, 37 , 2-30.
9.Vardaxis, N. J.; Brans, T. A.; Boon, M. E.; Kreis, R. W.; Marres, L. M., Confocal laser scanning microscopy of porcine skin: Implications for human wound healing studies. Journal of Anatomy 1997, 190, 601-611.
10.Potts, Russell. "Skin barrier: Principles of percutaneous absorption." Archives of Dermatology, 1997, 133.7, 924-924.
11.Rieger, M.; Rhein, L. D., Surfactants in cosmetics. CRC Press: 1997; Vol. 68.
12.Murdan, S.; Skin and Nail: Barrier Function, Structure, and Anatomy Considerations for Drug Delivery. Particle Sciences. Technical Brief, 2009, 3.
13.Roberts, R. ; Corneotherapy:The future of skincare has arrived, Les Nouvelle Esthetiques, 2004, 4
14.Roberts, M. S., Targeted drug delivery to the skin and deeper tissues: Role of physiology, solute structure and disease. Clinical and Experimental Pharmacology and Physiology 1997, 24, 874-879.
15.Schaefer H., Redelmeier T., Skin Barrier:Principles of Percutaneous Absorption,,Basel:Karger,1996,195.
16.Wang, S. P.; Chen, T. K.; Chen, R. E.; Hu, Y. Y.; Chen, M. W.; Wang, Y. T., Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. International Journal of Pharmaceutics 2012, 430 , 238-246.
17.Hoar, T.P., Schulman, J.H., Transparent Water-in-Oil Dispersions: the Oleopathic Hydro-Micelle, Nature, 1943 152: 102-107.
18.Shafiq, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F. J.; Khar, R. K.; Ali, M., Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics 2007, 66, 227-243.
19.Naseri, N.; Valizadeh, H.; Zakeri-Milani, P., Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull 2015, 5, 305-13.(26)
20.Lin, X. H.; Li, X. W.; Zheng, L. Q.; Yu, L.; Zhang, Q. Q.; Liu, W. C., Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2007, 311,106-111.(19)
21.Muller, R. H.; Radtke, M.; Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews 2002, 54, 131-155.(20)
22.Zur Muhlen, A.; Schwarz, C.; Mehnert, W., Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics 1998, 45 (2), 149-155.(21)
23.Wang, S. P.; Chen, T. K.; Chen, R. E.; Hu, Y. Y.; Chen, M. W.; Wang, Y. T., Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. International Journal of Pharmaceutics 2012, 430, 238-246.(22)
24.Qian, C.; Decker, E. A.; Xiao, H.; McClements, D. J., Solid Lipid Nanoparticles: Effect of Carrier Oil and Emulsifier Type on Phase Behavior and Physical Stability. Journal of the American Oil Chemists' Society 2011, 89 , 17-28.(23)
25.Naseri, N.; Valizadeh, H.; Zakeri-Milani, P., Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull 2015, 5, 305-13.(24)
26.Guimaraes, K. L.; Re, M. I., Lipid Nanoparticles as Carriers for Cosmetic Ingredients: The First (SLN) and the Second Generation (NLC). 2011; p 101-122.(25)
27.Tamjidi, F.; Shahedi, M.; Varshosaz, J.; Nasirpour, A., Design and characterization of astaxanthin-loaded nanostructured lipid carriers. Innovative Food Science & Emerging Technologies 2014, 26, 366-374.
28.Lucks, J.S., Müller, R. H.: Medication vehicles made of solid lipid particles (solid lipid Nanospheres SLN). Patent CA2119253A1,1991
29.Mehnert W., Mäder K., Solid lipid nanoparticles Production, characterization and applications. Advanced Drug Delivery Reviews 2012 ,64, 83–101
30.Radtke, M., Müller, R.H., Nanostructured lipid drug carriers. New Drugs 2, 2001,48–52
31.Jenning, V.; Schafer-Korting, M.; Gohla, S., Vitamin A-loaded solid lipid nanoparticles for topical use drug release properties. Journal of Controlled Release 2000, 66, 115-126.
32.Wissing, S. A.; Kayser, O.; Muller, R. H., Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug Delivery Reviews 2004, 56, 1257-1272.
33.Jenning, V.; Gohla, S., Comparison of wax and glyceride solid lipid nanoparticles (SLN (R)). International Journal of Pharmaceutics 2000, 196, 219-222.
34.Souto, E. B.; Mehnert, W.; Muller, R. H., Polymorphic behaviour of Compritol (R) 888 ATO as bulk lipid and as SLN and NLC. Journal of Microencapsulation 2006, 23, 417-433.
35.Fang, J. Y.; Fang, C. L.; Liu, C. H.; Su, Y. H., Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008, 70 , 633-40.
36.Kovacevic, A. B.; Muller, R. H.; Savic, S. D.; Vuleta, G. M.; Keck, C. M., Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: Preparation, characterization and physical stability investigation. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2014, 444, 15-25.
37.Puglia, C.; Bonina, F.; Rizza, L.; Blasi, P.; Schoubben, A.; Perrotta, R.; Tarico, M. S.; Damiani, E., Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies. Journal of Pharmaceutical Sciences 2012, 101, 301-311.
38.Sangsen, Y.; Wiwattanawongsa, K.; Likhitwitayawuid, K.; Sritularak, B.; Wiwattanapatapee, R., Modification of oral absorption of oxyresveratrol using lipid based nanoparticles. Colloids Surf B Biointerfaces 2015, 131, 182-90.
39.Hu, F. Q., Jiang, S. P.; Du, Y. Z.,Yuan, H.; Ye, Y. Q., Zeng, S., Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids and Surfaces B-Biointerfaces 2005, 45, 167-173.
40.Teeranachaideekul,V.Souto, E. B.; Junyaprasert, V. B.; Muller, R. H., Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - Development, physicochemical characterization and in vitro release studies. European Journal of Pharmaceutics and Biopharmaceutics 2007, 67, 141-148.
41.Hou, D., Xieb, C., Huangb, K., Zhuc, C., The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003,24, 1781–1785.
42.Goppert, T. M.; Muller, R. H., Plasma protein adsorption of Tween 80-and poloxamer 188-stabilized solid lipid nanoparticles. Journal of Drug Targeting 2003, 11, 225-231.
43.Von Rybinski, W.; Hill, K., Alkyl polyglycosides - Properties and applications of a new class of surfactants. Angewandte Chemie-International Edition 1998, 37, 1328-1345.
44.Han, F.; Li, S. M.; Yin, R.; Liu, H. Z.; Xu, L., Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2008, 315, 210-216.
45.Olbrich C., Kayser O. ,Muller R. H., Enzymatic degradation of Dynasan 114 SLN – effect of surfactants and particle size, Journal of Nanoparticle Research 4: 2002 , 121–129
46.Karn-Orachai, K.; Smith, S. M.; Saesoo, S.; Treethong, A.; Puttipipatkhachorn, S.; Pratontep, S.; Ruktanonchai, U. R., Surfactant effect on the physicochemical characteristics of gamma-oryanol-containing solid lipid nanoparticles. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2016, 488, 118-128.
47.Shin, G. H.; Kim, J. T.; Park, H. J., Recent developments in nanoformulations of lipophilic functional foods. Trends in Food Science & Technology 2015, 46 , 144-157.
48.Rong L., Charles F. S., Xiaoqing Y., Fang Z., Qingrong H., Stability and Bioaccessibility of β‑Carotene in Nanoemulsions Stabilized by Modified Starches, J. Agric. Food Chem., 2013, 61, pp 1249–1257
49.Salvia-Trujillo L., Qian, C. Martín-Belloso O., McClements D.J. , Modulating b-carotene bioaccessibility by controlling oil composition and concentration in edible nanoemulsions, Food Chemistry,2013,139 878–884
50.Choi A. Y., Kim C., Park H. Y., Kim H. O., Lee N. R., Lee K. E., Gwak H. S., Pharmacokinetic Characteristics of Capsaicin-Loaded Nanoemulsions Fabricated with Alginate and Chitosan, J. Agric. Food Chem., 2013, 61, pp 2096–2102
51.Nabila B., François D., Elmira A., Frédéric M. D., Cédric P., Isabelle L., Michel L., Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA’s nanoemulsions, European Journal of Pharmaceutical Sciences ,2012,47 305–312
52.Pinheiro, A. C.; Lad, M.; Silva, H. D.; Coimbra, M. A.; Boland, M.; Vicente, A. A., Unravelling the behaviour of curcumin nanoemulsions during in vitro digestion: effect of the surface charge. Soft Matter 2013, 9, 3147-3154.
53.Kim, S. O., Ha, T. V. A., Choi, Y. J., & Ko, S. H.,Optimization of homogenization evaporation process for lycopene nanoemulsion production and its beverage applications. Journal of Food Science, 2014, 79. N1604-N1601.
54.Karadag, A., Yang, X., Ozcelik, B., & Huang, Q., Optimization of preparation conditions for quercetin nanoemulsions using response surface methodology.Journal of Agricultural and Food Chemistry, 2013, 61,2130-2139.
55.Sessa, M.; Balestrieri, M. L.; Ferrari, G.; Servillo, L.; Castaldo, D.; D'Onofrio, N.; Donsi, F.; Tsao, R., Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem 2014, 147, 42-50.
56.Qian, C., Decker, E. A., Xiao, H., & McClements, D. J., Impact of lipid nanoparticlephysical state on particle aggregation and b-carotene degradation: potential limitations of solid lipid nanoparticles. Food Research International, 2013, 52, 342-349.
57.Pandita, D., Kumar, S., Poonia, N., & Lather, V., Solid lipid nanoparticle esenhance oral bioavailability of resveratrol, a natural polyphenol. Food Research International, 2014, 62, 1165-1174.
58.Wang, P.; Zhang, L.; Peng, H.; Li, Y.; Xiong, J.; Xu, Z., The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl 2013, 33, 4802-8.
59.Salminen, H.; Gommel, C.; Leuenberger, B. H.; Weiss, J., Influence of encapsulated functional lipids on crystal structure and chemical stability in solid lipid nanoparticles: Towards bioactive-based design of delivery systems. Food Chemistry 2016, 190, 928-937.
60.Carneiro, G.; Silva, E. L.; Pacheco, L. A.; de Souza-Fagundes, E. M.; Correa, N. C. R.; de Goes, A. M.; de Oliveira, M. C.; Ferreira, L. A. M., Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles. International Journal of Nanomedicine 2012, 7, 6011-6020.
61.Seetapan, N.; Bejrapha, P.; Srinuanchai, W.; Ruktanonchai, U. R., Rheological and morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid nanoparticles (SLNs). Micron 2010, 41, 51-58.
62.Farboud, E. S.; Nasrollahi, S. A.; Tabbakhi, Z., Novel formulation and evaluation of a Q10-loaded solid lipid nanoparticle cream: in vitro and in vivo studies. International Journal of Nanomedicine 2011, 6, 611-617.
63.Wang, S. P.; Chen, T. K.; Chen, R. E.; Hu, Y. Y.; Chen, M. W.; Wang, Y. T., Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies. International Journal of Pharmaceutics 2012, 430, 238-246.
64.Hejri, A., Khosravi, A., Gharanjig, K., & Hejazi, M., Optimisation of the formulation of b-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chemistry, 2013,141, 117-123.
65.Fang, M., Jin, Y., Bao, W., Gao, H., Xu, M., Wang, D., et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. International Journal of Nanomedicine 2012, 7, 5395-5404.
66.Keck, C. M., Baisaeng, N., Durand, P., Prost, M., Meinke, M. C., & Müller, R. H., Oil-enriched, ultra-small nanostructured lipid carriers (usNLC): a novel delivery system based on flipeflop structure. International Journal of Pharmaceutics, 2014, 477, 227-235.
67.61.Lacatusu, I., Mitrea, E., Badea, N., Stan, R., Oprea, O., & Meghea, A., Lipid nanoparticles based on omega-3 fatty acids as effective carriers for lutein delivery. preparation and in vitro characterization studies. Journal of Functional Foods, 2015, 5 1260-1269.
68.Gokce E.H, Korkmaz E.,DelleraE.,SandriG.,Bonferoni M C.,OzerO.,Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications,International Journal of Nanomedicine 2012:7 1841–1850
69.Sangsena Y. ,Wiwattanawongsa K.,Likhitwitayawuidd K.,Sritularakd B.,Wiwattanapatapeea R., Modification of oral absorption of oxyresveratrol using lipid basednanoparticles, Colloids and Surfaces B: Biointerfaces 2015, 131,182–190
70.Aditya, N. P.; Macedo, A. S.; Doktorovov, S.; Souto, E. B.; Kim, S.; Chang, P. S.; Ko, S., Development and evaluation of lipid nanocarriers for quercetin delivery: A comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). Lwt-Food Science and Technology 2014, 59 (1), 115-121.
71.Okonogi S., Riangjanapatee P., Physicochemical characterization of lycopene-loaded nanostructured lipid carrier formulations for topical administration, International Journal of Pharmaceutics, 2015,478, 726–735
72.PugliaC. ,Damiani E. , Offerta A.,Rizza L. ,Tirendi G. G.,Tarico M. S. ,Curreri S. ,Bonina F. , Perrotta R. E., Evaluation of nanostructured lipid carriers (NLC) and nanoemulsions as carriers for UV-filters: Characterization, in vitro penetration and photostability studies, European Journal of Pharmaceutical Sciences ,2014,51, 211–217
73.Muller, R. H.; Radtke, M.; Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews 2002, 54, S131-S155.
74.Svilenov H., Tzachev C., Solid Lipid Nanoparticles – A Promising Drug Delivery System, Nanomedicine,2012,188-213
75.Huang, Z. R.; Lin, Y. K.; Fang, J. Y., Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 2009, 14, 540-54.
76.Üner, M. "Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems." Die Pharmazie-An International Journal of Pharmaceutical Sciences 61.5 (2006): 375-386.
77.Nik, A. M.; Langmaid, S.; Wright, A. J., Nonionic Surfactant and Interfacial Structure Impact Crystallinity and Stability of beta-Carotene Loaded Lipid Nanodispersions. Journal of Agricultural and Food Chemistry 2012, 60, 4126-4135.
78.Salminen, H.; Aulbach, S.; Leuenberger, B. H.; Tedeschi, C.; Weiss, J., Influence of surfactant composition on physical and oxidative stability of Quillaja saponin-stabilized lipid particles with encapsulated omega-3 fish oil. Colloids Surf B Biointerfaces 2014, 122, 46-55.
79.Liu, L.; Tang, Y.; Gao, C.; Li, Y.; Chen, S.; Xiong, T.; Li, J.; Du, M.; Gong, Z.; Chen, H.; Liu, L.; Yao, P., Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B: Biointerfaces 2014, 115, 125-31.
80.Salminen, H.; Aulbach, S.; Leuenberger, B. H.; Tedeschi, C.; Weiss, J., Influence of surfactant composition on physical and oxidative stability of Quillaja saponin-stabilized lipid particles with encapsulated omega-3 fish oil. Colloids Surf B Biointerfaces 2014, 122, 46-55.
81.Jenning, V.; Gysler, A.; Schafer-Korting, M.; Gohla, S. H., Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. European Journal of Pharmaceutics and Biopharmaceutics 2000, 49, 211-218.
82.Ammar, H. O.; Ghorab, M. M.; Mostafa, D. M.; Ibrahim, E. S., Folic acid loaded lipid nanocarriers with promoted skin antiaging and antioxidant efficacy. Journal of Drug Delivery Science and Technology 2016, 31, 72-82.
83.Loo, C.; Basri, M.; Ismail, R.; Lau, H.; Tejo, B.; Kanthimathi, M.; Hassan, H.; Choo, Y., Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int J Nanomedicine 2013, 8, 13-22.
84.Wissing, S. A.; Muller, R. H., The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. European Journal of Pharmaceutics and Biopharmaceutics 2003, 56, 67-72.
85.Wissing S.A., Müller R.H., Cosmetic application for solid lipid nanoparticles (SLN). Int .J.Pharm.2003, 254, 65-68.
86.Wissing S.A., Müller R.H., A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. International journal of cosmetic science. 2001,23,233-243.
87.Villalobos-Hernandez, J.; Muller-Goymann, C. C., Novel nanoparticulate carrier system based on carnauba wax and decyl oleate for the dispersion of inorganic sunscreens in aqueous media. European Journal of Pharmaceutics and Biopharmaceutics 2005, 60, 113-122.
88.Miki, W., Biological functions and activities of animal carotenoids. Pure and Applied Chemistry 1991, 63.
89.Panis, G.; Carreon, J. R., Commercial astaxanthin production derived by green alga Haematococcus pluvialis: A microalgae process model and a techno-economic assessment all through production line. Algal Research-Biomass Biofuels and Bioproducts 2016, 18, 175-190.
90.Pashkow, F. J.; Watumull, D. G.; Campbell, C. L., Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease. American Journal of Cardiology 2008, 101, 58D-68D
91.Wolf, A. M.; Asoh, S.; Hiranuma, H.; Ohsawa, I.; Iio, K.; Satou, A.; Ishikura, M.; Ohta, S., Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. Journal of Nutritional Biochemistry 2010, 21, 381-389.
92.Todd Lorenz R.,Gerald R. C., Commercial potential for Haematococcus microalgae as a natural source of astaxanthin ,Tibtech april 2000 .18
93.Freitas, C.; Muller, R. H., Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN (TM)) dispersions. International Journal of Pharmaceutics 1998, 168, 221-229.
94.Kovacevic, A. B.; Muller, R. H.; Savic, S. D.; Vuleta, G. M.; Keck, C. M., Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: Preparation, characterization and physical stability investigation. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2014, 444, 15-25.
95.Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products, Center for Drug Evaluation and Research (CDER) 1999
96.Oecd guideline for the testing of chemicals:Skin Absorption: in vitro Method, 2000,428.
97.Diembeck W., Beck H., Kiffer B.,” Test Guidelines for In Vitro Assessment of Dermal Absorption and Percutaneous Penetration of Cosmeti Ingredients”,Food and Chemical Toxicologe, 1999, 37: p191-205
98.Monti, D.; Tampucci, S.; Chetoni, P.; Burgalassi, S.; Saino, V.; Centini, M.; Staltari, L.; Anselmi, C., Permeation and Distribution of Ferulic Acid and Its alpha-Cyclodextrin Complex from Different Formulations in Hairless Rat Skin. Aaps Pharmscitech 2011, 12, 514-520.
99.Jores, K.; Mehnert, W.; Drechsler, M.; Bunjes, H.; Johann, C.; Mader, K., Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. Journal of Controlled Release 2004, 95, 217-227.
100.Lin, X. H.; Li, X. W.; Zheng, L. Q.; Yu, L.; Zhang, Q. Q.; Liu, W. C., Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids and Surfaces a-Physicochemical and Engineering Aspects 2007, 311 , 106-111.
101.95.Kovacevic, A. , Savic, Vuleta, G. , Muller, R.H., Keck, C.M. ,Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC):Effects on size, physical stability and particle matrix structure, International Journal of Pharmaceutics,2011 406, 163–172
102.Freitas, C.; Muller, R. H., Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN (TM)) dispersions. International Journal of Pharmaceutics 1998, 168 , 221-229.
103.Elwira L., Elżbieta S.,Jan O.,Influence of process parameters on properties of Nanostructured Lipid Carriers (NLC) formulation,2013, Vol. 60,773–777
104.Fiume M.M., Heldreth, B., Bergfeld, W.F., Belsito, D.V., Hill, R.A., Klaassen, C.D.,Liebler, D., Marks Jr., J.G., Shank, R.C., Slaga, T.J., Snyder, P.W., Andersen, F.A. ,Safety assessment of decyl glucoside and other alkyl glucosides as used incosmetics. Int. J. Toxicol. 2013, 32, 22S–48S.
105.Matthies, W., Jackwerth, B., Krachter, H.-U.Dermatological properties of alkyl polyglycosides. In: Hill, K., von Rybinski, W., Stoll, G. (Eds.), Alkyl Polyglycosides: Technology, Properties and Applications. VCH Verlagsgesellschaft mbH Weinheim and VCH Publishers Inc., New York, 1997, pp. 169–177.
106.Keck, C. M.; Kovacevic, A.; Muller, R. H.; Savic, S.; Vuleta, G.; Milic, J., Formulation of solid lipid nanoparticles (SLN): The value of different alkyl polyglucoside surfactants. International Journal of Pharmaceutics 2014, 474, 33-41.
107.Taghizadeh, S. M.; Moghimi-Ardakani, A.; Mohamadnia, F., A statistical experimental design approach to evaluate the influence of various penetration enhancers on transdermal drug delivery of buprenorphine. J Adv Res 2015, 6 , 155-62.
108.Mennini, N.; Cirri, M.; Maestrelli, F.; Mura, P., Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation. Int J Pharm 2016, 515,684-691.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top